




# Supplementary Figure 1



## Supplementary Figure 2



# Supplementary Figure 3



Supplementary Table 1: Summary of 2.5 yr follow-up

|               | T8 CR                    | T8 CW                    | T8 CQ                    | T8 NN       | T8 NCW                   | T8 CWCR                  | IA2                      | GAD                      | 2h C-peptide             |
|---------------|--------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Prevalence %  |                          |                          |                          |             |                          |                          |                          |                          |                          |
| Start         | 76.2                     | 61.9                     | 38.1                     | 28.6        | 71.4                     | 81.0                     | 90.5                     | 95.2                     | 100                      |
| End           | 61.9                     | 52.4                     | 19.0                     | 23.8        | 66.7                     | 71.4                     | 90.5                     | 85.7                     | 85.7                     |
| Titer (index) |                          |                          |                          |             |                          |                          |                          |                          | (pmol/ml)                |
| Start         | 0.184±0.238              | 0.155±0.233              | 0.040±0.088              | 0.045±0.014 | 0.177±0.248              | 0.165±0.151              | 0.683±0.348              | 0.329±0.396              | 1.360±0.402              |
| End           | 0.102±0.174 <sup>a</sup> | 0.059±0.101 <sup>a</sup> | 0.021±0.072 <sup>b</sup> | 0.035±0.114 | 0.071±0.125 <sup>a</sup> | 0.103±0.113 <sup>a</sup> | 0.448±0.313 <sup>a</sup> | 0.298±0.409 <sup>b</sup> | 0.440±0.467 <sup>a</sup> |
| Final Titer % | 53.3±36.2                | 36.5±20.7                | 41.9±30.3                | 80.8±13.8   | 42.3±19.7                | 55.8±24.2                | 63.3±28.6                | 84.6±92.5                | 30.2±27.8                |
| (n)           | (15)                     | (13)                     | (8)                      | (5)         | (14)                     | (16)                     | (19)                     | (20)                     | (21)                     |

Antibody prevalence, antibody titer and C-peptide are calculated for the entire group (n=21). Final titer % are calculated for data where the initial indices exceeded 0.07.

Results are the mean±SD where shown: a.  $p<0.001$ ; b.  $p<0.005$  compared to antibody levels at disease onset (Wilcoxon matched pairs test)

Supplementary Table 2: Summary of 12 year follow-up group

|               | T8 CR                    | T8 NCW                   | T8 CWCR                  | IA2                      | GAD                      | C-peptide   |
|---------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------|
| Prevalence %  |                          |                          |                          |                          |                          |             |
| Start         | 57.4                     | 49.2                     | 70.5                     | 73.8                     | 63.9                     | NA          |
| End           | 13.1                     | 18.0                     | 39.3                     | 47.5                     | 32.4                     | 27.1        |
| Titer (index) |                          |                          |                          |                          |                          | (pmol/ml)   |
| Start         | 0.241±0.453              | 0.155±0.288              | 0.146±0.180              | 0.363±0.357              | 0.238±0.345              | NA          |
| End           | 0.037±0.125 <sup>a</sup> | 0.033±0.089 <sup>a</sup> | 0.028±0.059 <sup>a</sup> | 0.093±0.212 <sup>a</sup> | 0.177±0.359 <sup>b</sup> | 0.074±0.096 |
| Final Titer % | 11.7±15.8                | 13.0±14.4                | 12.1±14.4                | 17.1±25.5                | 23.4±40.0                | NA          |
| (n)           | (35)                     | (25)                     | (37)                     | (42)                     | (36)                     |             |

Antibody prevalence, antibody titer and C-peptide are calculated for the entire group (n=61). Final titer % are calculated for data where the initial indices exceeded 0.07.

Results are the mean±SD where shown: a.  $p<0.001$ ; b.  $p<0.005$  compared to antibody levels at disease onset (Wilcoxon matched pairs test)